BPC-157 soft tissue healing review 2019 explained

The BPC-157 soft tissue healing review by Daniel Gwyer, Nicholas Wragg and Samantha Wilson was published in 2019 in the journal Cell and Tissue Research. The authors work at Loughborough University in the United Kingdom. Their paper, Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing, is one of the few independent reviews of this peptide written outside the research group that discovered it. This article explains what the review set out to do, how the authors went about it, what they concluded and where the open questions remain.

What the BPC-157 soft tissue healing review asked

The authors start from a practical problem. Injuries to tendons, ligaments and skeletal muscle are common, often slow to heal and sometimes recur. Several experimental therapies based on growth factors are being tested in animal models. According to the review, these approaches have drawbacks: the growth factors are unstable in the body, they depend on carrier materials and they usually have to be applied locally and directly to the injury site.

Against this background, the authors asked a simple question: does the published literature support BPC-157 as a feasible candidate for healing and functional restoration of damaged soft tissue? They focused on three tissue types: tendon, ligament and skeletal muscle. If you are new to the peptide, our guide on what BPC-157 is gives the background on its origin and sequence.

How the BPC-157 soft tissue healing review was done

This paper is a narrative literature review, not an experiment. The authors did not treat animals or cells themselves. Instead, they collected and critically read the existing studies on BPC-157 in musculoskeletal soft tissue and summarised the results. The review covers injury models of different kinds, which the authors group into traumatic injuries (for example a cut or crushed tendon) and systemic insults (for example disturbances in blood electrolytes that damage muscle).

Because it is a review, there is no sample size, no control group and no statistical test of its own. The strength of the paper lies in the overview it provides and in the critical questions the authors raise about the underlying studies. The abstract does not state how many primary studies were included or which search strategy was used, so the review should not be read as a formal systematic review with a predefined protocol.

What the BPC-157 soft tissue healing review found

The central finding is stated clearly in the abstract: all studies investigating BPC-157 that the authors examined reported consistently positive and prompt healing effects. This applied across injury types, both traumatic and systemic, and across a wide range of soft tissues.

Several more specific points come out of the review:

• Tendon and ligament: The authors see the most promise for tissues that have a poor blood supply and few cells, such as tendons and ligaments. These tissues are known to heal slowly, and the animal data suggested that BPC-157 could support recovery there.

• Skeletal muscle: Muscle injury models suggested a beneficial effect not only after direct trauma but also after systemic insults. The abstract names hyperkalaemia (too much potassium in the blood) and hypermagnesaemia (too much magnesium) as examples.

• Adverse reactions: The authors note that few studies reported any adverse reactions to BPC-157 in the animal models.

Based on this, the authors conclude that BPC-157 has, in their words, huge potential and that it has promise as a therapy following further development. They also stress that the precise healing mechanisms still need to be understood before any clinical use could be considered.

Limitations of the BPC-157 soft tissue healing review

The authors are open about the weaknesses of the evidence base, and these limitations deserve as much attention as the positive findings:

• Animal models only: The majority of the studies reviewed were performed on small rodents, mainly rats. The abstract states that the efficacy of BPC-157 is yet to be confirmed in humans.

• Few research groups: Over the past two decades, only a handful of groups have performed in-depth studies on this peptide. Most of the literature comes from one group in Zagreb. Independent replication is therefore limited.

• Mechanism unclear: The authors state that the healing mechanism is not understood in detail.

• Review design: A narrative review summarises what others have published. It cannot correct for publication bias, where positive results are more likely to be published than negative ones. If all reviewed studies are positive, this may partly reflect what was published rather than what was found.

• No quantitative synthesis: The paper does not pool data in a meta-analysis, so it does not give an effect size for how much faster healing was.

No specific funding source for the review is named in the abstract. The authors are academic researchers, which is a point in favour of independence compared with studies from the original discovery group.

What this means for BPC-157 research

For researchers, the review is useful in two ways. First, it confirms that the preclinical signal for BPC-157 in soft tissue healing is consistent across many animal models. Second, it defines the gaps that future work should fill: independent replication in other laboratories, larger animal models, clear dose-response data and mechanistic studies that explain how the peptide acts on tendon, ligament and muscle cells.

The review does not provide evidence for effects in humans, and it does not recommend any use outside controlled research. Anyone reading claims about BPC-157 online should keep this distinction in mind. Related compounds studied in the same field are covered in our comparison of BPC-157 and TB-500, and the full range of compounds for this research area is listed in our healing and recovery peptides collection. For laboratories that work with the peptide, our BPC-157 10 mg is supplied as lyophilised powder for research use.

Sources

• Gwyer D, Wragg NM, Wilson SL (2019). Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cell and Tissue Research, 377(2), 153-159. doi:10.1007/s00441-019-03016-8

This article summarises published research for information only. It is not medical advice. All products on this site are sold for laboratory research use only and are not intended for human or veterinary use.